BIOGEN INC.

Biological Products, (No Diagnostic Substances)·CAMBRIDGE, MA·FY end 12/31·CIK 875045

CEO Pay Ratio

113:1

Christopher A. Viehbacher

CEO Total Comp

$23.6M

Christopher A. Viehbacher

Median Employee

$208,335

Revenue

$9.9B

FY 2025

Net Income

$1.3B

FY 2025

Free Cash Flow

$2.1B

FY 2025

Net Margin

13.1%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

1.83%

For every $1,000 of profit, $18.29 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$9.9B	$9.7B	$9.8B	$10.2B	$11.0B
Gross Profit	—	—	—	—	—	—
Operating Income	—	—	—	—	$2.8B	—
Net Income	$1.3B	$1.6B	$1.2B	$3.0B	$1.6B
Operating CF	$2.2B	$2.9B	$1.5B	$1.4B	$3.6B
Capex	$153.8M	$153.7M	$277.0M	$240.3M	$258.1M
Free Cash Flow	$2.1B	$2.7B	$1.3B	$1.1B	$3.4B
Buybacks	—	$0	$0	$750.0M	$1.8B
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	25.9%	—
Net Margin	13.1%	16.9%	11.8%	29.9%	14.2%
FCF Margin	20.7%	28.1%	12.9%	11.2%	30.8%
R&D / Revenue	—	—	—	—	—	—
Effective Tax	16.9%	—	—	—	—	—
Debt / Equity	—	—	0.47	0.47	0.58
Buybacks / FCF	—	0.0%	0.0%	65.6%	53.2%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Christopher A. ViehbacherPresident and Chief Executive Officer	$1.7M	$18.4M	—	$3.2M	$358.4K	$23.6M
Susan H. AlexanderExecutive Vice President, Chief Legal Officer	$1.0M	$5.8M	—	$1.1M	$197.1K	$8.1M
Nicole C. Murphy Headof Pharmaceutical Operations and Technology	$909.1K	$5.6M	—	$977.8K	$122.5K	$7.6M
Priya A. Singhal Headof Development	$929.7K	$5.6M	—	$951.7K	$123.9K	$7.6M